Biomedical Engineering

Primary Bioscience is a proteomics company that is developing a single-molecule protein sequencing that minimizes bias and allows for comprehensive analysis of unknown samples. While there are other companies that can identify known proteins, there are no alternative companies that provide de novo protein sequencing services on the market. Ultimately, Primary Bioscience’s technology opens doors to enhance research in personalized medicine, drug development, and biomarker discovery.

Northernmost™ is a medical device company developing NoMo™ Kidney Pump, a next-generation perfusion machine designed to modernize the preservation and transport of donor kidneys for transplantation. NoMo is purpose-built to obsolete the ice cooler, addressing the severe shortage of donor kidneys for the treatment for End Stage Renal Disease (ESRD). 

Moonrise medical is developing an AI-enabled ultrasound-based technology platform that optimizes the management of peripheral vascular disease, diabetes and foot wounds. The AI-enabled technology allows for sophisticated ultrasound evaluation, commonly managed by specialized providers, to be performed at-scale in the hands of non-experts. The technology is based on clinical evidence showing expedited wound healing and saving limbs from amputations.

D.Sole is a clinical decision support system that uses smart foot insoles and an ML platform for early detection and monitoring of foot complications in diabetic patients. With its data-driven insights into patient's feet, D.Sole can reduce foot complications by up to 98%, saving insurers an estimated $8 USD  billion annually. D.Sole's wearable technology seamlessly integrates into everyday footwear, enabling remote monitoring and proactive healthcare management for diabetic patients.

EyecareX leverages computer vision and generative AI to provide a comprehensive suite of automated, remote eye testing tools to enhance optometry clinic efficiency. EyecareX’s AI-powered platform enables patients to conduct tests at home via mobile app, streamlining the diagnostic process and boosting optometrist productivity by 200-300%. By outsourcing routine tests (visual acuity, color vision, extraocular muscle function) to patients, EyecareX effectively addresses capacity challenges in optometry clinics.

HTuO Biosciences is a drug discovery company that uses fundamental physics-based models of molecular interactions to optimize drugs and their targets. The computational platform brings together several advances to make drug-target simulations more reliable and better capture their emergent properties. This improved reliability enables HTuO to tackle hard to drug targets and ultimately expand the range of druggable targets, enabling new medicines for diseases that are currently untreatable.

Current Surgical is developing a digital ablation platform for the precise treatment of solid tumors. The product is a smart surgical needle leveraging ultrasound technology for real-time guidance of the needle-tip position and to selectively destroy the tumor and its margins using focused heat.

FibroDynamx is a drug discovery company developing therapies that promote tissue regeneration, without scarring. The platform is based on their Regenerative Blueprint, which combines proprietary data from their reindeer model with human wound healing data. Their first product (FD-001, a protein-based drug) prevents scar formation, and improves skin regeneration 10-fold in animal models of skin injury. 

AxCell Labs creates biocompatible soft tissue implants derived from bacterial cellulose using a proprietary process designed to enhance tissue regeneration through cell colonization. The depyrogenation process developed by AxCell Labs exceeds FDA standards by 5X and offers superior efficiency, reduces production time, and enhances safety and applicability of bacterial cellulose in medical applications such as reconstructive surgeries.

Vivamed develops a minimally invasive, wireless, battery-less implant to treat Obstructive Sleep Apnea (OSA). The implant simplifies surgery and recovery compared to existing Hypoglossal Nerve Stimulation devices by eliminating the need for large incisions and bulky batteries. This allows for wider physician adoption and reduces costs for healthcare systems.